Triple Helix Discovery Engine
Triple Helix Framework
Industry
Architects: Small & Medium Size Business (SMBs), Product Development, De-Risking, Validation, Building Niche & Emerging Markets
*Architects: Cancer & Oncology Companies _Pharmaceuticals & Biotechnology _ Prostate
INmune Bio, Inc.(NASDAQ: INMB)*

Organization & Developments: INmune Bio

UroGen Pharma

Parents

*INmune Bio (INMB) is a clinical-stage biopharma company that has a number of promising drugs in development that have the potential to address major problems like Alzheimer's and TRD (treatment-resistant depression).
*INmune Bio, Inc. is a publicly traded (INMB), clinical-stage biotechnology company focused on developing treatments that target the innate immune system to fight disease.
2020: Tiny Biotech Skyrockets To A Record High On Promising Alzheimer's News
2021: INmune Bio: Harnessing The Power Of The Innate Immune System
2022: INmune Bio, High Risk, Higher Reward_ seekingalpha.com
2024: FDA lifts clinical hold on INmune Bio’s Phase II Alzheimer’s trial
2024: INmune Bio: Caution Still Warranted But Upgrading To Hold_seekingalpha.com
2024: INmune Bio: NK Cell Therapy INKmune For mCRPC Is Another Shot On Goal
2024: INmune Bio: XPro Cognitive Readout In Sight, But Mind The Financial Dangers
2024: INmune Bio’s unique Alzheimer’s trial endpoint receives validation
2025: INmune Bio: CORDStrom Is A Game-Changer, As Investors Await Alzheimer's Results
2025: INmune Bio: Imminent Phase 2 Alzheimer's Readout Of Unique Asset Presents Interesting Speculative Opportunity
2025: INmune Bio: Phase 2 Trial In Alzheimer's Disease Is My Highest Risk-Reward Bet Of 2025_ seekingalpha.com
2025: INmune Bio: What's Left For Investors
2025:INmune Bio: XPro Trial Readout In Alzheimer's Disease Offers Big Opportunity